Last reviewed · How we verify

Adapalene 0.1% gel plus clindamycin 1% gel

All India Institute of Medical Sciences, Bhubaneswar · FDA-approved active Small molecule Quality 0/100

Adapalene 0.1% gel plus clindamycin 1% gel is a Small molecule drug developed by All India Institute of Medical Sciences, Bhubaneswar. It is currently FDA-approved.

At a glance

Generic nameAdapalene 0.1% gel plus clindamycin 1% gel
SponsorAll India Institute of Medical Sciences, Bhubaneswar
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adapalene 0.1% gel plus clindamycin 1% gel

What is Adapalene 0.1% gel plus clindamycin 1% gel?

Adapalene 0.1% gel plus clindamycin 1% gel is a Small molecule drug developed by All India Institute of Medical Sciences, Bhubaneswar.

Who makes Adapalene 0.1% gel plus clindamycin 1% gel?

Adapalene 0.1% gel plus clindamycin 1% gel is developed and marketed by All India Institute of Medical Sciences, Bhubaneswar (see full All India Institute of Medical Sciences, Bhubaneswar pipeline at /company/all-india-institute-of-medical-sciences-bhubaneswar).

What development phase is Adapalene 0.1% gel plus clindamycin 1% gel in?

Adapalene 0.1% gel plus clindamycin 1% gel is FDA-approved (marketed).

Related